NEW YORK (GenomeWeb) – Korean firm Seegene announced today that it has signed a memorandum of understanding with Hamilton to further develop the Seegene random access system.
The random access system is a molecular diagnostics solution that provides results within the same day. The system incorporates a universal nucleic acid extraction protocol which can be applied to a variety of samples, including blood, urine, stool, and sputum. These capabilities will be enabled through the partnership by integrating simultaneous and high multiplex real-time PCR testing on Hamilton's liquid handling platforms, Seegene said.
The firm also noted that it plans to complete the development of its digitalized development system through the collaboration with Hamilton. Finishing the digitalized development system will enable automation of initial reagent development to final quality control for the random access system.
"With the completion of [our] system, molecular diagnostics utilization will greatly increase as order-to-report on the same day allows hospitals to conduct molecular diagnosis, [which] will lead to a breakthrough in achieving on-time customized patient care," Seegene Founder and CEO Jong Yoon Chun said in a statement.
Last year, the South Korean company partnered with Spain's Institut Català d'Oncologia to conduct studies of its diagnostic products using clinical specimens.